| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g | |||
| Other Sizes |
Gentamicin sulfate (Centicin; Refobacin; Septigen sulfate; Uromycine; Oksitselanim; Lyramycin) is a potent aminoglycoside antibiotic widely used in the intensive care unit (ICU) to treat several types of bacterial infections such as bone infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, and sepsis among others. It has activity against both gram-positive and gram-negative bacteria and can inhibit several strains of mycoplasma in tissue culture. Gentamicin also inhibits DNase I with an IC50 of 0.57 mM. Gentamicin sulfate is a complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1(subA), obtained from Micromonospora purpurea and related species.
| Targets |
Aminoglycoside antibiotic; DNase I (IC50 = 0.57 mM)
|
|---|---|
| ln Vitro |
Gentamicin is harmless to tissue culture monolayers, does not affect viral replication, and is a more effective antibiotic activator than combined penicillin-streptomycin [2]. Gentamicin has been demonstrated to be bactericidal against a broader range of organisms (Pseudomonas aeruginosa, Proteus spp., and Streptococcus faecalis) and has been successfully employed as an additive in mycology to limit the growth of bacteria. generates streptomycin and penicillin [2]. Gentamicin is stable at autoclaving temperatures, harmless to rhesus monkey kidney, HeLa, and human amniotic cells, and does not interfere with the cellular effects generated by some polioviruses and echoviruses in tissue cultures [2]. Several Micromonospora species generate gentamicin [3]. RNA [3].
|
| ln Vivo |
Injectable and mouse formulations of gentamicin sulfate have shown strong antimicrobial activity against Y. pestis in infection models using mice [3]. Mice treated with gentamicin sulfate (0.27 g/kg) demonstrated a marked decrease in bacteria on foreign bodies [4]. 】.
|
| References | |
| Additional Infomation |
Gentamicin sulfate is the sulfate form of gentamicin, a fermented antibiotic complex. It consists of three chemically related aminoglycosides. It is a white to pale yellow powder. pH (4% solution) 3.5 to 5.5. Odorless. (NTP, 1992) National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Database. Research Triangle Park, North Carolina. Gentamicin sulfate is the sulfate form of gentamicin, a broad-spectrum aminoglycoside antibiotic complex produced by fermentation of Micromonospora purpurea or M. echinospora, and possesses antibacterial activity. Gentamicin is a thermostable complex containing gentamicin C1, C1a, C2, C2a, and C2b. Gentamicin sulfate is a small molecule drug, with its clinical trials reaching Phase IV (covering all indications). It was first approved in 1970 and currently has 7 approved indications and 10 investigational indications. This drug has been placed on a black box warning list by the U.S. Food and Drug Administration (FDA). It is a complex antibiotic produced by Micromonospora purpurea, containing three components: gentamicin sulfate C1, C2, and C1A.
|
| Molecular Formula |
C24H55N7O11S3*
|
|---|---|
| Molecular Weight |
561.65 (Average)
|
| Exact Mass |
1487.86917
|
| CAS # |
1405-41-0
|
| Related CAS # |
Gentamicin;1403-66-3
|
| PubChem CID |
9855350
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
797.6ºC at 760 mmHg
|
| Melting Point |
218-237°C
|
| Flash Point |
436.2ºC
|
| Hydrogen Bond Donor Count |
26
|
| Hydrogen Bond Acceptor Count |
40
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
101
|
| Complexity |
1930
|
| Defined Atom Stereocenter Count |
36
|
| SMILES |
O=S(O)(O)=O.O[C@]1(C)C(NC)[C@@H](O)[C@@H](O[C@H]2C(N)C[C@H](N)[C@@H](O[C@@H]3[C@H](N)CC[C@@H]([R])O3)[C@@H]2O)OC1.NC[*].C[C@H]([*])N.C[C@H]([*])NC.[R=].[or].[or]
|
| InChi Key |
RDEIXVOBVLKYNT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H43N5O7.C20H41N5O7.C19H39N5O7.H2O4S/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20;1-8(21)12-5-4-9(22)18(30-12)31-15-10(23)6-11(24)16(13(15)26)32-19-14(27)17(25-3)20(2,28)7-29-19;1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17;1-5(2,3)4/h9-20,25-29H,5-8,22-24H2,1-4H3;8-19,25-28H,4-7,21-24H2,1-3H3;8-18,24-27H,3-7,20-23H2,1-2H3;(H2,1,2,3,4)/t9?,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+;8?,9-,10+,11-,12+,13+,14-,15-,16+,17-,18-,19-,20+;8-,9+,10-,11+,12-,13+,14+,15-,16+,17+,18+,19-;/m110./s1
|
| Chemical Name |
mixtures of three isomers (Gentamicins C1, C2, and C1(subA).
|
| Synonyms |
Gentamicin sulfate; Bristagen; U-Gencin; Gentacidin; Garacin; Garamycin; Gentak; Apogen; NSC-82261; Refobacin; Sch 9724; Gentafair
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 30 mg/mL
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia
CTID: NCT04041791
Phase: Phase 3 Status: Completed
Date: 2024-07-08
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
